Journal
CANCER
Volume 116, Issue 20, Pages 4718-4726Publisher
WILEY
DOI: 10.1002/cncr.25259
Keywords
epithelial membrane protein-2; endometrial cancer; metachronous; tissue microarray; tumor biomarker
Categories
Funding
- National Institutes of Health [T32 CA 009056-32, HD48540, CA131756]
- Early Detection Research Network NCI [CA-86, 366]
- Iris Cantor Seed Grant
- UCLA Jonsson Comprehensive Cancer Center
Ask authors/readers for more resources
BACKGROUND: Endometrial cancer (EC) is a common malignancy worldwide. It is often preceded by endometrial hyperplasia, whose management and risk of neoplastic progression vary. Previously, the authors have shown that the tetraspan protein epithelial membrane protein-2 (EMP2) is a prognostic indicator for EC aggressiveness and survival. Here the authors validate the expression of EMP2 in EC, and further examine whether EMP2 expression within pre-neoplastic lesions is an early prognostic biomarker for EC development. METHODS: A tissue microarray (TMA) was constructed with a wide representation of benign and malignant endometrial samples. The TMA contains a metachronous cohort of cases from individuals who either developed or did not develop EC. Intensity and frequency of EMP2 expression were assessed using immunohistochemistry. RESULTS: There was a stepwise, statistically significant increase in the average EMP2 expression from benign to hyperplasia to atypia to EC. Furthermore, detailed analysis of EMP2 expression in potentially premalignant cases demonstrated that EMP2 positivity was a strong predictor for EC development. CONCLUSIONS: EMP2 is an early predictor of EC development in preneoplastic lesions. In addition, combined with our previous findings, these results validate EMP2 as a novel biomarker for EC development. Cancer 2010; 116: 4718-26. (C) 2010 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available